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A B S T R A C T
Understanding how health care system structures, processes, and available resources facilitate
and/or hinder the delivery of quality cancer care is imperative, especially given the rapidly changing
health care landscape. The emerging field of cancer care delivery research (CCDR) focuses on how
organizational structures and processes, care delivery models, financing and reimbursement,
health technologies, and health care provider and patient knowledge, attitudes, and behaviors
influence cancer care quality, cost, and access and ultimately the health outcomes and well-being
of patients and survivors. In this article, we describe attributes of CCDR, present examples of
studies that illustrate those attributes, and discuss the potential impact of CCDR in addressing
disparities in care. We conclude by emphasizing the need for collaborative research that links
academic and community-based settings and serves simultaneously to accelerate the translation
of CCDR results into practice. The National Cancer Institute recently launched its Community
Oncology Research Program, which includes a focus on this area of research.
J Clin Oncol 33:2705-2711. © 2015 by American Society of Clinical Oncology
INTRODUCTION
US health care systems are evolving rapidly in re-
sponse to concerns about quality, cost, reimburse-
ment, and access. Practices are merging or affiliating
with health systems, and health systems are consoli-
dating.1 New payment approaches that incorporate
explicit cost and quality goals have spurred experi-
mentation with service delivery models, such as ac-
countable care organizations, shared savings
approaches, expanded roles for interdisciplinary
team members, and the patient-centered medical
home. Cancer care has not been immune to these
changes, and expert reviews have drawn attention to
the various ways care delivery has fallen short of its
goal of providing consistent, high-quality cancer
care in diverse settings.2,3 In response, researchers
and practitioners have sought to strengthen the evi-
dence base that supports cancer care provision, en-
hance care coordination, and improve both patient
outcomes and care experiences. Achieving these
goals within the context of a changing health care
system is challenging; the evolving incentive struc-
tures sometimes support but often impede these
improvements.
This combination of a dynamic health care en-
vironment and the need to further improve the
quality, consistency, and efficiency of care demands
a better understanding of how cancer care is deliv-
ered across diverse settings and of the financial, or-
ganizational, and behavioral factors that interact
with clinical knowledge to shape outcomes. Cancer
care has distinctive characteristics; these include
complex provider and patient decision making, an
evolution of patient needs along the cancer control
continuum, and the requirement to coordinate
multiple treatment modalities and transitions in
care within a multidisciplinary setting.4 These char-
acteristics motivate a care delivery research effort in
the oncology context that integrates system-wide
factors and addresses the issues unique to cancer.
The emerging field of cancer care delivery research
(CCDR) offers an opportunity to examine these fac-
tors with greater attention to their multilevel influ-
ence on patient outcomes.
This article defines CCDR and identifies five
core attributes using illustrative examples of
practice-changing care delivery research con-
ducted in oncology or general practice settings.
We considered a study to be potentially practice
changing if it generated evidence sufficiently ro-
bust and generalizable to warrant application by
clinicians, organizations, and policy makers. Ex-
amples were assembled from seminal reviews,
empirical evidence, and discussions with health
services researchers and are provided to highlight
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key issues, research needs, and opportunities. We give special at-
tention to the important contribution CCDR makes toward ad-
dressing health disparities. Considerations for expanding CCDR in
the community setting are also addressed, including the ongoing
challenges of capturing research-quality data from rapidly evolving
electronic health records and related information systems.5 We
conclude with an introduction to the recently launched National
Cancer Institute (NCI) Community Oncology Research Program
(NCORP), a network that builds on previous NCI investments in
community-based clinical research,6-8 and includes a focus on
community-based CCDR.
CONCEPTUALIZING CCDR
Building on the definition of health services research proposed by
Lohr and Steinwachs,9 the NCI characterizes CCDR as “the multidis-
ciplinary field of scientific investigation that studies how social factors,
financing systems, organizational structures and processes, health
technologies, and health care provider and patient behaviors affect
access to cancer care, the quality and cost of cancer care, and ultimately
the health and well-being of cancer patients and survivors.”10 A hall-
mark of CCDR is the generation of new knowledge to inform practice
change, defined as clinically important and sustained modification of
the structures and processes of cancer care delivery to improve clinical
outcomes, enhance the patient experience, and optimize value.
The scope of CCDR encompasses individuals, families, pro-
viders, teams and health care organizations, payers, policymakers,
communities, populations, and their interactions.9,11 CCDR is dis-
tinguished from quality improvement by its focus on developing
new and generalizable knowledge about the effectiveness, accept-
ability, cost, optimal delivery mode, active ingredients, and causal
mechanisms that influence outcomes and affect the value of cancer
care, across diverse settings and populations.12 Quality improve-
ment activities focus on systematic efforts by a health care organi-
zation or system to monitor and raise the standards of system
performance and care delivery.13 CCDR findings can be applied by
decision makers at the local level to inform quality improvement
activities and reimbursement policies, as well as in the develop-
ment of practice guidelines and standards.
CCDR complements cancer clinical trials, which typically focus
on the efficacy and safety of new therapies and the testing of new
approaches to prevention and supportive care within the confines of
the controlled trial setting. Understanding how multilevel systems and
contextual factors influence the structures, processes, and outcomes of
cancer care delivery is essential to enacting practice change14 and is
especially important when patient characteristics alone are insuf-
ficient to explain variations in outcomes. CCDR also provides an
opportunity to examine how clinician and health system factors
affect equity in cancer care for diverse racial/ethnic groups and
medically underserved populations.
Although historically, most health care delivery research has been
conducted in primary care, early examples of CCDR within commu-
nity settings, such as the NCI Community Clinical Oncology Pro-
gram8 and the NCI Community Cancer Centers Program,6 have
informed changes in community oncology practice. CCDR study
designs include observational studies based on analyses of existing or
newly collected data on patients, clinicians, and/or organizations en-
gaged in the practice of oncology; pragmatic trials; intervention stud-
ies testing new approaches and processes of care delivery; and
dissemination and implementation studies comparing approaches to
improve oncology practice.
ATTRIBUTES OF CCDR
We believe that CCDR studies are most likely to have the greatest
impact on practice change if they encompass one or more of five
attributes: (i) address problems salient to patients and clinicians, (ii)
engage clinicians as active collaborators in the design and conduct of
studies, (iii) use standardized measures of health care quality, (iv)
examine causal pathways and active ingredients of practice change,
and (v) incorporate diverse settings and samples (Fig 1). These attri-
butes were identified through literature review and extensive discus-
sions with CCDR experts.
Evidence-based practice change: 
clinically important and sustained 
modification of the structures and processes 
of cancer care delivery to improve clinical 


























Fig 1. Attributes of cancer care delivery
research (CCDR) that can lead to
evidence-based practice change.
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Saliency to Patients and Clinicians
CCDR studies that are most likely to improve practice are those
focused on problems of importance to both patients and clinicians.
Study aims that incorporate patient and clinician perspectives and
reflect the constraints and incentives in real-world practice settings
have the greatest likelihood of leading to meaningful and sustained
practice changes.15 For example, addressing symptoms and well-being
is an essential component of effective palliative care, and these out-
comes are highly salient to patients, families, and clinicians. The Aus-
tralian Palliative Care Outcomes Collaboration has identified
clinician- and patient-reported measures that reflect the delivery of
high-quality palliative care, systematically incorporating standardized
data elements into a national system for audit, clinician feedback, and
practice benchmarking designed to drive improvement in the delivery
of palliative care. Importantly, the system also allows programs to
compare and contrast models of service delivery and deployment of
resources, motivating program enhancements that improve the value
of care while remaining responsive to variations in patient needs and
preferences based on local context. A recent study demonstrated that
collecting information important to both patients and clinicians at the
point of care and incorporating that information into a system that
provides feedback and benchmarking result in improved clinical out-
comes in symptom control and patient/family well-being.16
Clinician Collaboration in Design and Conduct
of Studies
An important element of CCDR is that clinicians are actively
engaged in the design and conduct of research aimed at improving
care delivery processes and clinical outcomes. This is especially
important in complex intervention studies, where research design
and data collection occur at multiple levels. Involving front-line
clinicians in study design and implementation strengthens external
validity and yields important insights about intervention feasibility
and acceptability.17
In collaboration with clinicians, investigators in the outpatient
breast cancer chemotherapy clinic at Dana-Farber Cancer Institute
developed an intervention to reduce errors and gaps in care
through improved communication.18 The team developed tools and
procedures to reduce risks in priority process areas by improving
communication and interactions among various team members. Im-
plementation of these interventions improved safety, efficiency, qual-
ity, and satisfaction for both patients and clinicians.18
The STEP-UP (Study to Enhance Prevention by Understanding
Practice) trial provides an example of a collaboratively developed care
delivery study in a primary care setting. This group-randomized trial
engaged 79 practices to determine whether a set of tailored interven-
tions would improve preventive services delivery in three areas:
health-habit counseling, cancer screening, and immunization.19 Prac-
tices in the intervention group received a nurse-led assessment of their
current performance in these three areas. They were then presented
with tools and approaches for practice improvement, and teams chose
which strategies to implement in their particular setting. The interven-
tion group also received practice facilitation, as well as feedback and
peer benchmarking. One and 2 years after implementation, the inter-
vention group showed a significant and sustained increase in the
frequency of both health-habit counseling and screening compared
with the control group.20
Use of Standardized Measures of Care Quality
Standardized structure, process, and outcome measures of
care quality are an essential feature of CCDR.21 These indicators
provide a rich source of ideas for CCDR by identifying practice
variation and targets for practice change. CCDR studies that incor-
porate well-accepted quality measures are also more likely to be
feasible across diverse settings and to generate findings that can be
directly applied in practice. Oncology quality measures have been
identified by organizations including the American Society of Clin-
ical Oncology (ASCO), the American Society of Radiation Oncol-
ogy, the Oncology Nursing Society, the American College of
Surgeons Commission on Cancer, the National Comprehensive
Cancer Network, and the National Quality Forum. For example,
the National Surgical Quality Improvement Program, a hospital-
based data collection system sponsored by the American College of
Surgeons, is considered the gold standard for evaluating surgical
outcomes in cancer.22 Program data revealed that many breast
surgery centers had higher than expected tumor re-excision rates as
a result of the identification of positive surgical margins remaining
after initial tumor resection.23 McCahill et al24 subsequently con-
ducted an observational study at four practice sites. They found
that variability in re-excision rates was explained by inconsisten-
cies in the minimum distance to clear margins among practices
rather than by patient factors or a practice’s procedure volume.
Variability in clear margin distances was found both among insti-
tutions and among surgeons within an institution. These findings
motivated guideline development addressing margin distances in
breast-conserving surgery for women with early-stage breast can-
cer.25,26 Future CCDR studies might explore whether guideline-
concordant care is being delivered and identify the factors that
contribute to practice variation after guideline dissemination,
which in some contexts may include weak evidence or patient
preferences.
Providing feedback to clinicians in the form of quality perfor-
mance data and benchmarking against peers can serve as a compo-
nent of a practice-change intervention and has shown some
efficacy in improving care delivery processes and outcomes.27 The
ASCO Quality Oncology Practice Initiative (QOPI) is a practice-
based quality monitoring program that collects data from partici-
pating practices on a wide range of process measures, including the
timeliness of care delivery and adherence to national guidelines.
QOPI provides practices with an analysis of their own data as well
as comparisons benchmarked to other participating practices. On-
cology practices with sustained participation in this program of
routine quality monitoring and feedback reported better perfor-
mance (eg, in quality measures of pain care and documentation of
hospice and palliative care discussions) than practices participating
in QOPI for the first time.28 A similar quality reporting system—
the Rapid Quality Reporting System (RQRS)—is a cancer registry–
based data system that provides continuous performance feedback
and benchmarking to participating hospitals. An evaluation com-
paring performance before and after RQRS implementation at 41
community cancer centers demonstrated significant improvement
in five breast and colorectal cancer (CRC) quality metrics after
RQRS implementation.29 Guideline adherence also increased by
39% and 25%, respectively, in uninsured and Medicaid patients
receiving radiation therapy after breast-conserving surgery.30
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Examination of Causal Pathways and Active
Ingredients of Practice Change
CCDR studies that yield the greatest insights include a focus on
isolating the causal mechanisms and active ingredients of a practice-
change intervention. Colquhoun et al12 recently specified a framework
describing considerations for developing, targeting, and testing inter-
ventions for practice change. They propose that successful practice-
change interventions are supported by empiric knowledge about the
active ingredients in the intervention, the causal mechanisms (pro-
cesses or mediators) by which an intervention effects change, the
mode of delivery, and the intended targets of the intervention.
A recent demonstration project illustrates the importance of
linking structure and process measures with outcomes. Clinical lead-
ers in four federally qualified health centers were trained to deliver a
practice facilitation intervention that incorporated a tracking system
for cancer screening and engaged primary care teams in identifying
and implementing strategies to improve uptake of effective screening
tests in underserved populations. The centers monitored progress
across several process measures: proportion of eligible patients screened
for breast, cervical, and CRCs; proportion screened who received timely
results; and proportion of abnormal screens definitively evaluated within
90 days.31 From 2005 to 2007, CRC screening rates increased from 8.6%
to 21.2%, and the program was scaled to more than 50 participating
centers. Additional studies are needed to confirm that improvements are
sustainable and to examine which aspects represent the active ingredients
in this practice-change intervention.
The underlying mechanisms and active ingredients of an inter-
vention are perhaps most apparent when process measures are linked
to resultant health outcomes. A study in 1999 reported high prescrip-
tion rates of hematopoietic colony-stimulating factors (CSFs) for
indications outside of the ASCO guidelines for prophylaxis and
management of neutropenia.32 A subsequent analysis similarly
showed that CSF prescription in patients at risk for neutropenia
was not supported by ASCO guidelines.33 ASCO identified reduc-
tion in guideline-discordant CSF prescription as one of its top-five
strategies for improving care and decreasing cost.34,35 A recent
study in 22 community oncology practices providing service to
nearly 100,000 patients demonstrated that a peer-to-peer consul-
tative intervention increased guideline concordance in CSF pre-
scription and produced substantial cost savings, with no increase in
febrile neutropenic events.36
Russell et al37 recently reported the findings of a multicenter
randomized controlled trial to improve lung cancer treatment out-
comes. The CCDR intervention consisted of a baseline audit of care
quality and patient experience, peer review, and coaching of teams to
develop individualized quality improvement plans. Although the in-
tervention was effective in optimizing the interval from diagnosis to
treatment, the active ingredients in the intervention were not disen-
tangled. In another example, an ongoing study to improve prostate
cancer outcomes using a multifaceted practice improvement inter-
vention and a stepped-wedge, mixed-methods design will yield infor-
mation about efficacy and isolate the mechanisms of change and active
ingredients within the intervention.38 Mixed methods are an impor-
tant consideration in the design of CCDR studies and can help to
evaluate the acceptability of a practice-change intervention, gauge
implementation fidelity, and identify the active ingredients and mech-
anisms of provider and organizational change.
Incorporation of Diverse Settings and Samples
For CCDR results to be reproducible and widely generalizable,
samples and settings should be representative of the diverse contexts of
care delivery. For example, a single-site study testing routine electronic
symptom surveillance and alert-triggered symptom management in
patients undergoing cancer surgery showed positive effects on symp-
tom severity.39 However, a multisite study of a similar intervention in
patients receiving cancer chemotherapy did not confirm these bene-
fits.40 Thus, as intervention testing moves from efficacy to effective-
ness, pragmatic trial designs and samples drawn from community-
based settings and diverse populations become essential. Evidence
developed in multisite, community-based contexts may also acceler-
ate implementation of research-tested interventions in routine clinical
care. As an example, in a quasi-experimental study conducted among
underserved Latina women with a new breast cancer diagnosis, a
higher proportion of women who received a navigation intervention
initiated treatment within 30 days, and navigation also reduced the
time from diagnosis to treatment initiation to 21 days (v 48 days in
control group).41 These results were independent of cancer stage at
diagnosis and other characteristics at the individual or clinic level. A
cluster-randomized trial of nurse navigation also demonstrated that
women with breast cancer who receive the intervention have fewer
unmet psychosocial needs, have a more favorable patient experience,
and report more favorable ratings of care coordination and informa-
tion provision.42
On the basis of the body of evidence from trials showing the
efficacy of community-based models of patient navigation, particu-
larly for underserved populations, the Commission on Cancer
identified the provision of navigation programs as one of its patient-
centered standards for program accreditation.43 At the same time,
implementation of navigation programs has varied widely, and com-
parative evidence about the cost effectiveness of different navigation
models is still needed.44 One potential reason for uneven adoption
may be that many navigation studies have been conducted in a small
number of clinics or within regionally based health systems and there-
fore may not be viewed as having general applicability. CCDR studies
that address the cost effectiveness of different navigation models and
barriers to scaling across diverse community settings will provide
important knowledge to support widespread adoption.
Another example of a study matched to its implementation set-
ting is the evaluation conducted by Kaiser Permanente Southern Cal-
ifornia (KPSC) of the effectiveness of aromatase inhibitors (AIs) and
tamoxifen in reducing contralateral breast cancer incidence. The study
used a retrospective cohort design and sampled from 15 medical
centers and more than 100 outpatient clinics.45 Results showed that
risk reduction was greatest in the group with the highest adherence to
AIs and tamoxifen, leading KPSC to incorporate AI and tamoxifen
adherence measures into its electronic health record. KPSC then de-
veloped a program of systematic outreach to women who were over-
due for prescription refills, resulting in more timely refill rates.46 This
study also illustrates how data routinely collected in health records can
highlight suboptimal practice patterns and be used simultaneously to
drive enhancements to care delivery protocols. Understanding how to
tailor this new care pathway for implementation in organizational
settings beyond KPSC would enhance generalizability.
The importance of employing diverse settings and samples in
CCDR is also exemplified by the Colorectal Cancer Care Collaborative
established by the Department of Veterans Affairs (VA) to reduce the
Kent et al
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time from a positive CRC screening test to diagnostic colonoscopy.47
Building on the success of this collaborative, all VA facilities were
required to submit a flow map of their local CRC screening and
diagnostic process, describe their quality improvement activities to
enhance fecal occult blood testing follow-up, and report quarterly
the proportion of patients who screened fecal occult blood test
positive and who received a diagnostic colonoscopy within 60 days.
From these national data, Powell et al48 determined that two infra-
structural improvements and three process improvements were
predictive of higher proportions of patients receiving a timely
diagnostic colonoscopy. Understanding how to generalize these
process improvements beyond the VA could advance care delivery
processes across diverse settings.
ADDRESSING HEALTH CARE DISPARITIES
In developing CCDR studies that address cancer care disparities, all of
the attributes of CCDR highlighted remain relevant. However, be-
cause of the lingering effects of historical injustices on current percep-
tions and attitudes, as well as barriers related to language, culture,
knowledge, and understanding, CCDR studies of cancer care dispari-
ties require careful attention to patient perspectives and to the often
essential role of community-based organizations as mediators of prac-
tice improvement.7,49 In addition, the negative impact of cancer-
related financial burden on well-being, access to care, and clinical
outcomes is recognized increasingly as an issue for an even broader
range of patients than those traditionally conceptualized as under-
served,50 and is thus a crucial research topic for CCDR.
In one example of a CCDR intervention to address health care
disparities, the state of Delaware implemented a program to reduce
racial disparities in CRC incidence and mortality.51 The three-part
program increased CRC screening among minority groups, improved
access of these groups to CRC treatment, and implemented patient
navigation to improve efficiency and continuity of care. Subsequently,
state-level disparities between whites and blacks in rates of screening
colonoscopy, CRC incidence, and CRC mortality were virtually elim-
inated. The program included statewide reimbursement for colonos-
copy for uninsured residents with incomes up to 250% of the federal
poverty level, deployed nurse navigators at each of the five acute care
hospital sites in the state, and established the Delaware Cancer Treat-
ment Program to cover the costs of cancer care for 2 years for unin-
sured residents with household incomes up to 650% of the federal
poverty level. Future research is needed to understand the cost effec-
tiveness of wide-scale implementation of this model program.
EXPANDING CCDR IN COMMUNITY SETTINGS
What we have learned to date about the capacity of CCDR to influence
practice change is based largely on research conducted in integrated
health care delivery settings (eg, VA, Kaiser Permanente) and aca-
demic medical centers. This is because such integrated settings are
often better equipped to facilitate the rapid and widespread imple-
mentation of practice changes and typically have data resources that
support outcomes evaluation. In addition, CCDR studies conducted
outside these integrated systems are often performed at only one site
or in one geographic region, thereby limiting their generalizability.
There are also many barriers to integrating CCDR findings across
settings that use different health information technology systems.52
Thus, implementing these practice changes beyond their original
study settings remains a challenge.8
For CCDR to influence practice change across community set-
tings, studies must involve participants drawn from a diverse range of
community practice settings. Conducting CCDR within a broad net-
work such as NCORP that includes independent community prac-
tices, system-affiliated practices, and safety-net institutions could
substantially enhance the relevance and broaden the adoption of
CCDR findings in routine practice.53 In addition, with some notable
exceptions, we found few examples of multisite CCDR studies con-
ducted in community settings that focused on reducing disparities for
diverse and/or underserved populations. This gap might be addressed
by CCDR networks that are more broadly community based and that
specifically offer a network of care delivery sites that focus on improv-
ing cancer care services to underserved populations. In response to
this need, in August 2014, NCI launched NCORP. This new program
builds on 30 years of community-based clinical trials research
experience.7,8 NCORP, which currently comprises 34 community
sites, 12 minority/underserved sites, and seven research bases, pro-
vides a unique opportunity to conduct CCDR in settings that reflect
real-world practice conditions and diverse patient populations.
NCORP has the potential to contribute to much-needed progress in
improving clinical outcomes and enhancing the efficiency, access,
quality, and affordability of care across the full spectrum of oncology
practice settings and the care continuum.
DELIVERING ON THE PROMISE OF CCDR
This article has described important characteristics of CCDR, which pro-
duces new knowledge that can be applied across diverse settings to im-
prove cancer care quality and outcomes, and has provided examples of
studies that support practice change. A key finding is that the impact of
CCDRisgreatestwhenitisconductedindiversepracticesettings.Success-
ful implementation of CCDR outside integrated health care systems will
require multilevel partnerships across academic and community settings
and a coordinated research infrastructure including integrated data sys-
tems. It will also require investment and commitment from health care
providersandotherkeystakeholderstocontinuouslyimprovequalityand
enact health policy that supports these efforts.
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